Case Study:
Understand How to Impact Patient Adherence Using Artificial Intelligence.
AI Provides Previously Unseen Insights to Increase Adherence to Medication
There are so many causes of non-adherence, but these differ depending on the therapy area, beliefs, culture and more. So how can you understand the causes of non-adherence for your brand and your market – from real world data and not doing more market research? You already have social listening data, call center data, market research data and a whole lot more. All of this can be analyzed using Artificial Intelligence to help you identify nuances that you had not seen previously.
The Client Problem
The pharma company had a challenge with adherence dropping off for their brand after 3 months. They had results of the market research but implementing the recommendations had not resulted in markedly better adherence performance. The market research team wanted to see if AI could analyze their existing data alongside other real-world data.
The Solution
They had a wealth of market research data, social listening data, call center data and more. All of the data was put into a proprietary platform which uses Natural Language Processing alongside Machine Learning to combine the data sources, including the social listening data, and analyze it to uncover nuances that were previously not picked up. [Note: Find out whose proprietary platform in the Eularis membership – it was not ours!]
The Outcome
The client was able to get numerous insights into the different causes of non-adherence that had not been previously uncovered with the market research alone approach. This led them into being able to design interventions that had a positive impact on increasing adherence to their medication.
To achieve these kinds of results, join Eularis membership today.
Latest News
Read our latest blogs here.
The Future of AI Is Living Intelligence – Here’s Why You Need It
What Is Living Intelligence in AI and Why Does It Matter for the Future? In the rapidly changing world of pharmaceuticals today, AI systems that
Artificial Intelligence is on the C Suite Agenda – but Ineffectively Implemented
It is good to finally see that big data and Artificial Intelligence analytics are now on the pharma C-Suite agenda with a recent survey by NewVantage Partners showing that 85.5% of major corporations are working on big data initiatives. This is because many companies have now measured and proven the value of these for growing their pharma brands and companies.
AI + Smart Devices: The New Frontline Against Chronic Disease
Chronic diseases have emerged as one of the most significant public health challenges of the 21st century. According to the World Health Organization, chronic diseases